Targeted NGS in fetuses with isolated and non-isolated CHD achieved a high diagnostic yield in our cohort, with an acceptable turnaround time for the prenatal setting. Our results have important implications for clinical management and genetic counseling. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

This study aimed to estimate the radiation dose and cancer risk to adults in England, the USA and Hong Kong associated with retrospectively and prospectively electrocardiogram (ECG)-gated coronary computed tomography angiography (CTA) using currently practised protocols in Hong Kong. The doses were simulated using the ImPACT spreadsheet. For retrospectively ECG-gated CTA with pitches of 0.2, 0.22 and 0.24, the effective doses were 27.7, 23.6 and 20.7 mSv, respectively, for males and 23.6, 20.0 and 18.8 mSv, respectively, for females. For prospectively ECG-gated CTA, the effective dose was 3.7 mSv for both males and females. A table of lifetime attributable risks (LAR) of cancer incidence was set up for the English population for the purpose of estimating cancer risk induced by low-dose radiation exposure, as previously reported for US and Hong Kong populations. From the tables, the LAR of cancer incidence for a representative 50-year-old subject was calculated for retrospectively ECG-gated CTA to be 0.112% and 0.227% for English males and females, respectively, 0.103% and 0.228% for US males and females, respectively, and was comparatively higher at 0.137% and 0.370% for Hong Kong males and females, respectively; for prospectively ECG-gated CTA, the corresponding values were calculated to be 0.014% and 0.035% for English males and females, respectively, and 0.013% and 0.036% for US males and females, respectively, and again were higher at 0.017% and 0.060% for Hong Kong males and females, respectively. Our study shows that prospectively ECG-gated CTA reduces radiation dose and cancer risks by up to 87% compared with retrospectively ECG-gated CTA.

Background: Advanced GC pts have limited treatment options and poor prognosis. Immune checkpoint inhibitors (ICIs) showed promising activities in pretreated pts, especially for those with high PD-L1 expression. Blockade of TGF-b pathway may enhance the tumor response to ICIs.Methods: This phase I study composed of a dose escalation and expansion (ESC & EXP) period in solid tumors and multiple clinical expansion cohorts. Based on findings of the ESC & EXP period, 30 mg/kg Q3W was determined as RP2D. In the GC clinical expansion cohort, pts who had progressed on or were intolerant to 2L standard therapies were given SHR-1701 at the RP2D. Prior ICIs were not allowed. Primary endpoint was ORR per RECIST v1.1.Results: 35 pts were enrolled: stage IV, 91.4%; 2L prior systemic therapies, 54.3%. By Apr 6, 2021, median SHR-1701 exposure was 12.0 wk (range 3.0-64.9). Of the 31 pts with post-baseline scan(s), 16 (51.6%) pts showed tumor shrinkage. 1 CR and 7 PR were achieved, and ORR was 25.8% (95% CI 11.9-44.6). 2 PR were not confirmed yet as there was no consequent scan after first PR as of data cutoff. Confirmed ORR was 19.4% (95% CI 7.5-37.5; 1 CR + 5 PR; ongoing responses: 66.7% [4/6]). DCR was 41.9% (95% CI 24.5-60.9). CBR (CR + PR + SD23 wk) was 25.8% (95% CI 11.9-44.6). Median PFS was 1.4 mo (95% CI 1.3-9.6), and 6-mo PFS rate was 38.7% (95% CI 22.0-55.1). Median OS was not reached yet. Exploratory analyses showed a trend towards favourable responses for pts with a PD-L1 CPS 5 (Table ). Most common TRAEs (incidence >10% in 35 pts) were rash, increased AST/ALT, decreased FT3 and pruritus. Incidence of irAEs was 45.7%. Grade 3 or 4 TRAEs occurred in 17.1% of pts, and no pts died due to TRAEs. Incidence of grade 3 irAEs was 11.4%. Table: 1375P Efficacy outcomes* in all patients and subgroups by PD-L1 expression All patients (N[31) CPS <5 (N[10) CPS ‡5 (N[9) ORR, n (%; 95% CI) 6 (19.4%; 7.